Hundreds of women with hard-to-treat ovarian cancer can now be offered a new life-prolonging treatment, after NHS England approved its introduction. It is the first new drug for resistant ovarian cancer to be approved for more than 20 years.
Ovarian is the 18th most common type of cancer globally, affecting more than 300,000 women a year. More than three-quarters of patients are diagnosed at an advanced stage, making it harder to treat.
